Tumor-Dwelling Bacteria Linked to Very Early Recurrence in Liver Cancer

One of the most frustrating realities in liver cancer treatment is that even after a seemingly successful surgical resection, hepatocellular carcinoma—the most common form of primary liver cancer—can return with startling speed. A subset of patients experiences what clinicians call very early recurrence, in which the tumor reappears within weeks or a few months of the operation, often before any follow-up imaging could plausibly have guided a second intervention. Understanding why some tumors behave this way while others remain quiescent for years has become one of the central questions in hepatobiliary oncology. A new study published in BMC Medicine adds an unexpected dimension to that question by pointing not at the cancer cells themselves, nor at the immune system in isolation, but at the bacteria living inside the tumor tissue.

The research, led by Shu-jie Pang, Zhe Sun, and Da-peng Xu of the Eastern Hepatobiliary Surgery Hospital at Naval Medical University in Shanghai, together with colleagues, set out to map the microbial communities residing within hepatocellular carcinoma and to ask whether the composition of those communities differs between patients whose disease recurs very early after surgery and those who remain disease-free. The team collected tumor tissue and paired adjacent non-tumor tissue from 131 patients with hepatocellular carcinoma and subjected the samples to 16S ribosomal RNA sequencing, a technique that reads out a genetic barcode shared by all bacteria and thereby allows researchers to identify which microbial taxa are present in a sample without needing to culture the organisms in the laboratory.

The first finding addresses a lingering controversy in the field. Intratumoral bacteria have been reported in liver cancer before, but studies have disagreed about whether the microbial composition of tumors actually differs from that of the surrounding, apparently healthy liver tissue. In this cohort, the authors found that overall microbial diversity—the number of distinct bacterial types and their relative abundances—did not differ significantly between tumor and normal tissue. What did differ was composition: the identity of the bacterial players shifted between tumor and adjacent tissue, and there was marked inter-individual heterogeneity, meaning that no two patients carried quite the same intratumoral microbial signature. Bacterial composition also overlapped substantially among tumor tissue, adjacent liver tissue, and bile, a pattern consistent with the idea that the biliary tract may serve as a conduit through which microbes reach the liver parenchyma.

The pivotal result, however, emerged when the researchers stratified patients by clinical outcome. When the intratumoral microbiota of patients who experienced very early recurrence was compared with that of patients who did not, one genus stood out: Bifidobacterium. This group of anaerobic, Gram-positive bacteria—famous as a beneficial inhabitant of the healthy human gut—was significantly less abundant within the tumors of patients whose cancer came back very early. In other words, a paucity of Bifidobacterium inside the tumor was associated with the most aggressive postoperative behavior of the disease. The association held up in an external validation dataset generously provided by Professor Yilei Mao and his team at Peking Union Medical College Hospital, strengthening the case that the signal is not an artifact of a single institution’s patient population.

To confirm that the sequencing signal reflected real bacteria rather than contamination, the team turned to fluorescence in situ hybridization, or FISH. This technique uses fluorescently labeled DNA probes that bind to complementary sequences in bacterial ribosomal RNA, allowing the organisms to be visualized directly within sections of tumor tissue under the microscope. The FISH experiments confirmed the physical presence of Bifidobacterium within hepatocellular carcinoma tissue, placing the bacterium inside the tumor microenvironment rather than merely detecting stray DNA that might have been introduced during sample handling.

With the association established, the researchers probed what Bifidobacterium might actually be doing inside the tumor. They divided tumor samples into those with high versus low abundance of the genus and performed transcriptomic sequencing, which measures the activity levels of all human genes expressed in the tissue. This revealed differentially expressed genes and pathways between the two groups, along with differences in the immune cell composition of the tumors as inferred from the expression profiles. Among the most notable molecular findings was that enrichment of Bifidobacterium correlated with reduced expression of BIRC5, the gene encoding baculoviral IAP repeat containing 5, a member of the inhibitor of apoptosis protein family. BIRC5, better known in the literature as survivin, is a well-characterized antagonist of programmed cell death and is frequently overexpressed in cancers, where it helps malignant cells evade the apoptotic signals that would otherwise eliminate them.

The functional implications of that transcriptional signature were tested with two complementary tissue-based assays. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling, universally abbreviated as TUNEL, detects the fragmented DNA that is a hallmark of cells undergoing apoptosis, the tightly regulated process of programmed cell death. Immunohistochemistry for cleaved caspase-3, the executioner enzyme that becomes activated only when a cell has committed to the apoptotic pathway, provided an independent readout of the same biology. Both assays told a consistent story: tumors rich in Bifidobacterium showed enhanced apoptotic activity, exactly as predicted by the reduced BIRC5 expression. The convergence of the transcriptomic data with the TUNEL and cleaved caspase-3 staining lends biochemical weight to what might otherwise have remained a purely correlational observation.

The mechanistic picture that emerges is intriguing, if still incomplete. Bifidobacterium is perhaps best known to immunologists for its role in cancer immunotherapy: prior work by other groups has shown that the abundance of this genus in the gut microbiome can determine whether mice and patients respond to immune checkpoint blockade, and fecal microbiota transplantation experiments have implicated it directly in that effect. The new study extends the relevance of this bacterium from the intestinal lumen to the interior of the tumor itself, and from the immune-activation axis to the apoptotic machinery of the cancer cell. If intratumoral Bifidobacterium suppresses survivin expression and thereby lowers the apoptotic threshold of tumor cells, its absence could plausibly permit residual malignant cells to survive the surgical insult and seed very early recurrence—although the authors are careful to note that causality has not been demonstrated and that the finding requires validation in multi-center cohorts.

Several caveats frame the interpretation of the work. The study was conducted at a single Chinese center, and liver cancer etiology varies considerably across the world, with hepatitis B virus dominating in East Asia while hepatitis C, alcohol, and nonalcoholic fatty liver disease drive the disease elsewhere; whether the microbiota-recurrence link generalizes across these different disease backgrounds remains to be seen. The 16S sequencing approach identifies bacteria only to the level of genus or species with limited resolution and cannot by itself reveal what the organisms are metabolically doing. And as with all studies of low-biomass tissues, distinguishing a genuine resident microbiota from environmental or procedural contamination is a persistent methodological challenge—one that the authors addressed with FISH confirmation and careful bioinformatics, but which continues to demand rigor across the field.

Nevertheless, the study opens a concrete translational avenue. If reduced intratumoral Bifidobacterium abundance is confirmed as a predictor of very early recurrence in larger, multi-center studies, it could eventually inform risk stratification after curative resection, identifying the patients who need the closest surveillance or adjuvant therapy. More ambitiously, the result feeds into a growing interest in microbiota-directed interventions—from probiotics to fecal microbiota transplantation—as adjuncts to cancer treatment. For now, the message is a sober and carefully documented one: the bacteria that live within liver tumors are not passive bystanders, and one familiar genus may hold a clue to why some hepatocellular carcinomas refuse to stay gone.

Subject of Research: Intratumoral microbiota and Bifidobacterium abundance in very early recurrence of hepatocellular carcinoma

Article Title: Intratumoral microbiota heterogeneity and Bifidobacterium abundance are linked to very early recurrence in hepatocellular carcinoma

Article References: Pang, S.-J., Sun, Z., Xu, D.-P., Shi, Y., Si-ma, H., Yang, N., & Yang, Y. (2026). Intratumoral microbiota heterogeneity and Bifidobacterium abundance are linked to very early recurrence in hepatocellular carcinoma. BMC Medicine. https://doi.org/10.1186/s12916-026-05271-3

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05271-3

Keywords: hepatocellular carcinoma, intratumoral microbiota, Bifidobacterium, very early recurrence, 16S rRNA sequencing, apoptosis, BIRC5, tumor microenvironment, FISH, immunohistochemistry, liver cancer, microbiome